Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Repligen Corporation stock

Own Repligen Corporation stock in just a few minutes.

Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Repligen Corporation employs 1,128 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Repligen Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Repligen Corporation share price

Use our graph to track the performance of RGEN stocks over time.

Repligen Corporation shares at a glance

Information last updated 2021-04-23.
52-week range$109.38 - $228.84
50-day moving average $199.37
200-day moving average $195.47
Wall St. target price$236.71
PE ratio 197.8198
Dividend yield N/A (0%)
Earnings per share (TTM) $1.11

Buy Repligen Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Repligen Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Repligen Corporation under- or over-valued?

Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Repligen Corporation's P/E ratio

Repligen Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 198x. In other words, Repligen Corporation shares trade at around 198x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Repligen Corporation's PEG ratio

Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Repligen Corporation's EBITDA

Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $103 million.

The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.

Repligen Corporation financials

Revenue TTM $366.3 million
Operating margin TTM 20.74%
Gross profit TTM $210.4 million
Return on assets TTM 2.88%
Return on equity TTM 4.63%
Profit margin 16.36%
Book value $27.92
Market capitalisation $12.1 billion

TTM: trailing 12 months

Shorting Repligen Corporation shares

There are currently 1.5 million Repligen Corporation shares held short by investors – that's known as Repligen Corporation's "short interest". This figure is 10.3% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Repligen Corporation shares can be evaluated.

Repligen Corporation's "short interest ratio" (SIR)

Repligen Corporation's "short interest ratio" (SIR) is the quantity of Repligen Corporation shares currently shorted divided by the average quantity of Repligen Corporation shares traded daily (recently around 494765.81469649). Repligen Corporation's SIR currently stands at 3.13. In other words for every 100,000 Repligen Corporation shares traded daily on the market, roughly 3130 shares are currently held short.

However Repligen Corporation's short interest can also be evaluated against the total number of Repligen Corporation shares, or, against the total number of tradable Repligen Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Repligen Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Repligen Corporation shares in existence, roughly 30 shares are currently held short) or 0.0318% of the tradable shares (for every 100,000 tradable Repligen Corporation shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Repligen Corporation.

Find out more about how you can short Repligen Corporation stock.

Repligen Corporation share dividends

We're not expecting Repligen Corporation to pay a dividend over the next 12 months.

Repligen Corporation share price volatility

Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $109.38 up to $228.835. A popular way to gauge a stock's volatility is its "beta".

RGEN.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 0.8218. This would suggest that Repligen Corporation's shares are less volatile than average (for this exchange).

Repligen Corporation overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site